Metropolitan Life Insurance Company (MetLife)’s Aratana Therapeutics, Inc. PETX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-4,118
| Closed | -$21.2K | – | 2685 |
|
|
2019
Q2 | $21.2K | Buy |
+4,118
| New | +$18.5K | ﹤0.01% | 2600 |
|
|
2019
Q1 | – | Sell |
-17,040
| Closed | -$104K | – | 2589 |
|
|
2018
Q4 | $104K | Hold |
17,040
| – | – | ﹤0.01% | 2240 |
|
|
2018
Q3 | $99.5K | Buy |
+17,040
| New | +$85.1K | ﹤0.01% | 2456 |
|
|
2018
Q1 | – | Sell |
-1,415
| Closed | -$7K | – | 2518 |
|
|
2017
Q4 | $7K | Sell |
1,415
-28,944
| -95% | -$177K | ﹤0.01% | 2500 |
|
|
2017
Q3 | $186K | Sell |
30,359
-90
| -0.3% | -$570 | ﹤0.01% | 2313 |
|
|
2017
Q2 | $220K | Buy |
30,449
+4,830
| +19% | +$29.7K | ﹤0.01% | 2282 |
|
|
2017
Q1 | $136K | Buy |
25,619
+3,883
| +18% | +$26.2K | ﹤0.01% | 2409 |
|
|
2016
Q4 | $156K | Sell |
21,736
-1,002
| -4% | -$8.1K | ﹤0.01% | 2482 |
|
|
2016
Q3 | $213K | Sell |
22,738
-2,971
| -12% | -$24.7K | ﹤0.01% | 2299 |
|
|
2016
Q2 | $162K | Buy |
+25,709
| New | +$165K | ﹤0.01% | 2470 |
|
|
2015
Q4 | – | Sell |
-20,686
| Closed | -$175K | – | 2663 |
|
|
2015
Q3 | $175K | Buy |
20,686
+518
| +3% | +$8.77K | ﹤0.01% | 2374 |
|
|
2015
Q2 | $305K | Buy |
20,168
+358
| +2% | +$5.17K | ﹤0.01% | 2107 |
|
|
2015
Q1 | $317K | Sell |
19,810
-2,328
| -11% | -$41.4K | ﹤0.01% | 1811 |
|
|
2014
Q4 | $394K | Buy |
22,138
+2,514
| +13% | +$31.3K | ﹤0.01% | 1931 |
|
|
2014
Q3 | $197K | Hold |
19,624
| – | – | ﹤0.01% | 2373 |
|
|
2014
Q2 | $306K | Buy |
+19,624
| New | +$278K | ﹤0.01% | 2190 |
|
Other funds holding PETX
Metropolitan Life Insurance Company (MetLife)'s PETX Position: Q3 2019 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 4,118 shares — an estimated $21.2K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in PETX in Q2 2014 and held it in 16 quarters. The position peaked at $394K in Q4 2014. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 4,118 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $21.2K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Aratana Therapeutics, Inc. in Q2 2014 and held it in 16 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Aratana Therapeutics, Inc. position peaked at $394K in Q4 2014.
- 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2019, filed 14 Nov 2019.